On being a good doctor. The number of research publications don’t tell you how good a doctor is at being a doctor. Neither do the number of book chapters or grants. Or academic rank. It’s a different skill set. Good doctors have stellar clinical acumen & empathy. #MedTwitter

On being a good doctor Part II (after being on the other side as a patient advocate) - Understand the patient and the clinical problem they face. It is more than just analyzing lab results and scans. 90% of diagnosis is history. - History taking/acquisition is a skill.

Looking forward to speaking on treatment of High-risk #myeloma at European Hematology Association conference in Milano in June - many thanks Myeloma Society and EHA for invite. In the meantime, hope people might enjoy our BSH - Haematology podcast on this topic: podbean.com/ew/pb-2734e-17…

The paper of the day: a landmark publication that is bound to serve as a reference for years to come! ⁦NatureRevClinOncol⁩ ⁦Thanos Dimopoulos⁩ ⁦COMy⁩ ⁦IACH⁩ ⁦Meral Beksac⁩ ⁦

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… European Hematology Association EMN Θεραπευτική Κλινική ΕΚΠΑ / NKUA Therapeutics

🚨 NEWS 🚨 European Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:

But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs! v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500... Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!

1/ New Blood Advances treasure trove of 🇩🇪 🇺🇸 data about bridging before CAR-T in #MMsm. Bigger is not better when it comes to bridging using chemotherapy... Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias & infections!

MjesTEC-5 ORR 100%, 95-100 CR, MRD- 100% including 10-6. #IMS2025 #mmsm

And #IMS25 Marc S. Raab adding that they even switched from NGF to NGS at 10^-6 to be sure... still 100% MRD neg across the board. Truly remains the best induction data in #MMsm the world has ever seen... and my guess is that IVIG is helping to lower AE profile substantially!

Exciting data from MajesTEC-5 by Dr. Raab. Tec-Dara based induction leading to ~100% MRD-negativity rate by NGS at 10^-6 post Cycle#6. At ~7 mo f/u risk of Grade 3 or higher infection ~37% (no deaths from infection yet). My thoughts: Is ASCT necessary with such deep response

Dr Rahul Banerjee (Rahul Banerjee, MD, FACP) of Fred Hutch Cancer Center shares his favorite presentations from #IMS25 and explains why he finds them interesting. #IMS2025 #mmsm Read more here: shorturl.at/xaGmE

1st results of the #GMMGHD7 imaging substudy presented at #IMS2025 ➡️ lower WB-MRI (MY-RADS) scores correlate with MRD negativity after induction in #mmsm Congrats to Marina Hajiyianni on receiving the Young Investigator Award for these great work! 👏

Well-deserved Marina Hajiyianni & Heidelberg Myeloma 🙌 #mmsm

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

#3 Phase III COBRA trial VRd vs KRd. Dytfeld et al. RCT with 250 patients showing better outcomes with KRd vs VRd. Goes against ECOG ENDURANCE trial where we found no difference. But not sure how this fits since we have moved to Dara VRd. #ASH25 Link: meetings-api.hematology.org/api/abstract/v…

#1 Teclistamab plus Daratumumab RCT in Relapsed myeloma. Tec-3 Majestec-3 marivi mateos Luciano J Costa Game-changing in 3 ways -Unprecedented efficacy, HR 0.17 -Changes SOC from monotherapy to Tec-Dara -New Dara-like dosing schedule for Tec #ASH25 Link: meetings-api.hematology.org/api/abstract/v…

Just in time for #ASH25 MRD in Myeloma: all your questions answered! How to use MRD assessment in practice and research. Saurabh Zanwar Leukemia Journal For a limited time get free access through this link: nam12.safelinks.protection.outlook.com/?url=https%3A%… The principles we discuss apply for all